Clinical trial

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived…

NCT00001512 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00001512
Title Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
Official title Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions B Cell Lymphoma, Follicular Lymphoma, Lymphoma
Intervention type Drug
Interventions Id-KLH Vaccine, GM-CSF
Enrollment 42
Start date Sep 9, 1996
Primary completion Mar 5, 2010
Completion Mar 5, 2010
First posted Nov 4, 1999
Last update posted Jul 2, 2017
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies